← Leaderboards
Sachin Wani
University Of Colorado Denver
$2,810,778
Attributed
$12,424,003
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,424,003 · 3
By mechanism
U01$12,039,865 · 2
U34$384,138 · 1
Top collaborators
- Nicholas J Shaheen9 shared
- Valerie L Durkalski5 shared
- Rhonda F Souza5 shared
- Chetan Bettegowda4 shared
- Amitabh Chak4 shared
- Sanford D Markowitz4 shared
- Joseph Edward Willis3 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Joann Lindenfeld$2,694,462
- Kerrie Moreau$13,944,323
- Nathaniel Tussing Greene$516,833
- Edward Abraham$8,831,231
Others in their field
Other Emerging Leaders on “High Grade Dysplasia”
- Daniel Jeong · H. Lee Moffitt Cancer Ctr & Res Inst$2,480,910
- Jennifer B Permuth · H. Lee Moffitt Cancer Ctr & Res Inst$2,480,910
- Gerald McMorrow · Veravanti, Inc.$1,995,368
- Erik Allen Jensen · Children'S Hosp Of Philadelphia$1,984,548
- Curtis Pickering · University Of Tx Md Anderson Can Ctr$1,700,122
- Ashish A. Deshmukh · University Of Texas Hlth Sci Ctr Houston$1,425,673
Research focus
High Grade DysplasiaMalignant Neoplasm Of EsophagusEnrollmentGuidelinesIncidenceImmunohistochemistryDiagnosisEndoscopyEsophagusFutureImageBiobankCostBiological MarkersBiomarker PanelDetectionDysplasiaEffectivenessBiopsyEsophageal AdenocarcinomaBarrett EsophagusFollow-UpComplicationMalignant Neoplasms
Grant awards (9)
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$1,742,655
U01 · FY2025 · DK · contact PI
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,048,823
U01 · FY2025 · CA
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$2,111,999
U01 · FY2024 · DK · contact PI
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$996,868
U01 · FY2024 · CA
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$2,130,120
U01 · FY2023 · DK · contact PI
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,028,348
U01 · FY2023 · CA
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$2,200,000
U01 · FY2022 · DK · contact PI
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$781,052
U01 · FY2022 · CA
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$384,138
U34 · FY2020 · DK · contact PI